PPARA and hypertensive disorder: In addition to the previous study, the PPAR-α activator, docosahexaenoic acid (DHA), abrogated the development of hypertension, decreased ICAM-1, VCAM-1, corrected structural abnormalities, and improved the endothelial dysfunction induced by Ang II [9, 18].